Senexis in the news - independent articles

Articles published in the trade press:

• Channel M Today (03/02/10), Dementia Report: Prof. Andrew Doig interviewed
• Business Weekly (21/01/10), Page IX: Senexis has qualities to become a "great"
• Business Weekly (26/11/09), Page IV: Senexis has ingredients to become global star
• Business Weekly (19/11/09), Page 4: Senexis file two further patents
• Cambridge Evening News (03/11/09), Page 19: Region's top performers put on a winning show
• Business Weekly (22/10/09), Page XV: Entrepreneurship encouraged at Babraham
• Cambridge Business (Q4 2009), Issue 4, Page 10: Confused about Alzheimer's?
• Business Weekly (15/10/09), Page 10: Q10: talking heads
• Business Weekly (08/10/09), Page 20: 2009 awards boost morale
• Business Weekly (30/09/09), Page 11: Epigenetics to revolutionise healthcare
• Business Weekly (17/09/09), Page 16: Great year as Senexis racks up the plaudits
• Business Weekly (10/09/09), Page 17: Awards 2009: Disruption, disruption, disruption
• BioWorld International (09/09/09) Senexis passes Wellcome Trust milestone
• BioWorld (04/09/09) Senexis secures funding from the Wellcome Trust to select candidate
• Cambridge Evening News (01/09/09) Business Section (page 17): Senexis grant boost
• BioWorld (27/08/09) Senexis awarded grant from EEDA for Alzheimer's drug
• Business Weekly (27/08/09), Page 13: Senexis awarded grant for Alzheimer's work
• Cambridge Evening News (07/07/09) Business Section (page 17): Senexis tackles disease
• Business Weekly (02/07/09), Page 8: Senexis wins funding to fight muscle disease
• Journal of UKSPA (May 2009), Page 41: Five years on the road to drug discovery
• UK Trade & Investment today (15/12/08) UK pharma firm collaborates on Alzheimer's test
• Australian Life Scientist (11/12/08) Alzhyme signs an agreement with Senexis
• Business Weekly (10/12/08) Senexis in Oz Alzheimer's diagnostics tie-up
• Business Weekly (27/11/08), Page 16: Senexis to expand into diagnostics
• Business Weekly (17/07/08), Page VII: Senexis' main focus on Alzheimer's disease
• Business Wire 2008 (12/06/08) The CNS Market 2008 Report
• Bio-Medicine (14/02/08) Senexis and O2H announce medicinal chemistry collaboration
• BIOTAQ (14/02/08) Senexis and O2H announce medicinal chemistry collaboration
• CNS Drug News (01/02/08) Senexis raises funds to further develop AD compounds
• Business Weekly (31/01/08), Page V: Senexis: unfolding the science of senescence
• Business Weekly (23/01/08) Senexis lands £2.9m Wellcome funding for Alzheimer's
• BioWorld International (22/01/08) Senexis awarded $5.7m from the Wellcome Trust
• BioCentury (21/01/08) Senexis receives $5.7 million from the Wellcome Trust
• Science Business (18/01/08) UK drug developer gets £3.7 million for Alzheimer's
• Dow Jones Venture Wire (18/01/08) Senexis swallows $7.3 million series A
• Silicon Fen Business Report (18/01/08) Senexis raises £2.9 million
• Chemical Business (17/01/08) Senexis secures £0.8 million from BTG
• Current Patents Gazette (13/04/07) Senexis files small molecule patent
• Business Week (16/01/07) Senexis and Daniolabs to collaborate
• News RX (11/04/06) Alzheimer's compounds licensed to Senexis
• Silicon Fen Business Report (04/02/06) BTG and the Wellcome Trust invest in Senexis
• Biospace (12/2/2005) Senexis and BioFocus collaborate to select development candidates for Senexis' Alzheimer's disease targets
• Chemistry & Industry (17/01/05) Movers and Shakers
• BioCentury (18/04/2005) Emerging Company Profile - Senexis: Break it up
• Genetic Engineering News (01/09/2004) Biotechnology Firms Settle in Cambridge, UK
• In Vivo Europe (01/07/2004) RX Starting Out: Senexis
• Current Opinion in Structural Biology (2003) Design strategies for anti-amyloid agents
• Biotechnology Investment Today (Summer 2003) Meptides: a potential treatment for neurodegenerative diseases
• Genetic Engineering News (01/02/2003) New UK Company targets Amyloidosis